In the natural history of chronic hepatitis type B, spontaneous cessation of hepatitis B virus (HBV) replication, characterized by the disappearance of serum HBeAg and HBV DNA and intrahepatic HBcAg, is usually associated with remission of liver disease. However, in some patients this event occurs late, when the liver damage, closely related to continuous HBV replication, has already progressed to cirrhosis, portal hypertension and hepatic failure (Pastore et al., 1977; Realdi et al., 1980) . Attempts to increase the rate of spontaneous cessation of viral replication or complete clearance of HBV have been made using different antiviral agents, including interferon (IFN)-alpha and beta (Dooley et al., 1986; Hoofnagle et al., 1988; Saracco et et., 1989; Eisenberg et sl., 1986) .
In this study we evaluated the efficacy of a low dosage of recombinant IFN-u (rIFN-u) in a randomized controlled study of adult patients with HBsAg and HBeAg positive chronic hepatitis.
Thirty heterosexual HBsAg chronic carriers, aged 18-55 years, were admitted to the study and randomly allocated to receive rlFN-u (14 patients) or no treatment (16 patients). All patients fulfilled the following criteria: presence of serum HBsAg, HBeAg and HBV DNA for at least 1 year, raised serum alanine, absence of serological markers for hepatitis delta virus (HDV) and human immunodeficiency virus (HIV), no history or other evidence of alcohol and intravenous drug abuse, and no previous therapy with antiviral drugs or corticosteroids.
The clinical, biochemical and histological features of the patients on entry into the study are listed in Table 1 . Each patient of the treated group received a standard dose of 4.5 million units (MU) of rlFN-u (Roferon-A; Hoffmann-La Roche Co. Ltd, Basel, Switzerland) three times a week i.m. for 16 consecutive weeks. Treated and untreated patients were evaluated for clinical symptoms and for biochemical parameters and HBV markers at regular intervals for 16 months after the start of the study. At the end of this follow-up another liver biopsy was performed. Table 2 shows the changes in HBV markers and alanine aminotransferase (AL1) levels in 28 patients (13 treated and 15 controls) at the end of therapy (16 weeks) and after 16 months of follow-up. Two patients, one in the treated group and one in the control group, were withdrawn from the study because of HIV and HDV superinfection, respectively. Only one patient belonging to the treated group cleared HBsAg and seroconverted to anti-HBs. During treatment,loss of serum HBV DNA and HBeAg was observed in seven out of 13 treated patients and in one out of 15 controls (P = 0.01). In the follow-up two more treated patients became HBV-DNA and HBeAg negative, while two of seven responders showed reactivation of viral replication with reappearance of HBV DNA and HBeAg in the serum and an increase in ALT levels. In the control group four more cases showed spontaneous disappearance of HBV DNA and seroconversion from HBeAg to anti-HBe.
In general, 16 months after the start of the study seven patients in the treated group and five in the control group (P = NS) were HBV DNA-negative.
Normalization of ALT occurred in all patients who cleared HBV DNA from the serum. The clearance of serum HBV DNA correlated with disappearance of HBcAg from the liver cells in all treated and untreated patients except for two treated cases. Of these two, one showed persistence of HBV DNA in the serum without HBcAg in the liver, whereas the other one cleared HBV DNA from the serum but showed only a reduction of HBcAg-positive hepatocytes on the second bioptic sample. A significant increase of HBcAg-positive cells with prevalent cytoplasmic reactivity was observed in the two patients who relapsed 6-9 In summary, in our controlled study the 16-week lowdose regimen of rlFN-cr seems to have been effective in inhibiting HBV replication in 50% of the treated patients, whilst a corresponding 7% of spontaneous clearance of the replication markers was observed in the untreated subjects. However, the regimen studied here does not appear to have had a permanent effect in all patients; in fact, at the end of the follow-up period there was no significant difference between the treated and the untreated group. In order to reduce the frequency of viral reactivation in the treated group, thus increasing the number of responders at the end of the follow-up, a more prolonged regimen of therapy seems to be indicated, and is also justified on account of the optimal tolerance of the drug at the doses used. This work was supported in part by a grant from the Ministero Pubblica Instruzione, Rome, Italy. months after discontinuation of IFNtreatment (from 5% to 39% and from 10% to 51%, respectively) ( Fig. 1) .
A significant regression of necro-inflammatory activity was observed on the second liver biopsy in six out of seven treated patients who had permanent loss of HBV DNA and normalization of ALT, while one remained unchanged. No significant changes in inflammatory infiltrate and hepatocellular necrosis were observed in the non-responder patients. Among the patients of the untreated group, a significant improvement in the degree of inflammation and necrosis was observed in four out of the five subjects who spontaneously cleared HBV-DNA from the serum; in the remaining patients, liver histology was unchanged in nine and worsened in two due to the appearance of initial cirrhosis.
In agreement with other studies (Dusheiko et al., 1986; Hoofnagle et al., 1988) , the response rate to rlFN-cr was less frequent in patients with milder forms of chronic hepatitis than in patients with more severe histological diagnosis and baseline high ALT levels. 
